Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) — Market Cap & Net Worth
Market Cap & Net Worth: Arcturus Therapeutics Holdings Inc (ARCT)
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) has a market capitalization of $393.66 Million ($393.66 Million) as of September 26, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13628 globally and #3266 in its home market, demonstrating a -18.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arcturus Therapeutics Holdings Inc's stock price $13.85 by its total outstanding shares 28423069 (28.42 Million). Also see total assets of Arcturus Therapeutics Holdings Inc for a full breakdown of the balance sheet.
Arcturus Therapeutics Holdings Inc Market Cap History: 2015 to 2026
Arcturus Therapeutics Holdings Inc's market capitalization history from 2015 to 2026. Data shows change from $1.25 Billion to $393.66 Million (-10.39% CAGR). Also see Arcturus Therapeutics Holdings Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Arcturus Therapeutics Holdings Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.64 Trillion | 0.01% | #365 of 976 |
|
NASDAQ Composite
IXIC
|
$42.21 Trillion | 0.00% | #1318 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.87 Trillion | 0.02% | #199 of 263 |
Weight: Arcturus Therapeutics Holdings Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Arcturus Therapeutics Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arcturus Therapeutics Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Arcturus Therapeutics Holdings Inc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.59x
Arcturus Therapeutics Holdings Inc's market cap is 2.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $417.82 Million | $20.38 Million | -$24.60 Million | 20.50x | N/A |
| 2017 | $225.96 Million | $13.00 Million | -$10.90 Million | 17.38x | N/A |
| 2018 | $128.76 Million | $15.75 Million | -$21.79 Million | 8.17x | N/A |
| 2019 | $308.96 Million | $20.79 Million | -$25.99 Million | 14.86x | N/A |
| 2020 | $1.23 Billion | $9.54 Million | -$72.15 Million | 129.26x | N/A |
| 2021 | $1.05 Billion | $12.36 Million | -$203.67 Million | 85.12x | N/A |
| 2022 | $482.06 Million | $205.75 Million | $9.35 Million | 2.34x | 51.56x |
| 2023 | $896.18 Million | $157.75 Million | -$29.73 Million | 5.68x | N/A |
| 2024 | $482.34 Million | $138.39 Million | -$80.94 Million | 3.49x | N/A |
| 2025 | $174.23 Million | $67.22 Million | -$65.78 Million | 2.59x | N/A |
Competitor Companies of ARCT by Market Capitalization
Companies near Arcturus Therapeutics Holdings Inc in the global market cap rankings as of September 26, 2026. Review Arcturus Therapeutics Holdings Inc tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Arcturus Therapeutics Holdings Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #339 globally with a market cap of $79.70 Billion USD.
- CSL Ltd (AU:CSL): Ranked #453 globally with a market cap of $60.74 Billion USD ( AU$85.85 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #507 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $526.19 |
| #339 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.70 Billion | $788.04 |
| #453 | CSL Ltd | AU:CSL | $60.74 Billion | AU$176.95 |
| #507 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $198.88 |
Arcturus Therapeutics Holdings Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Arcturus Therapeutics Holdings Inc's market cap moved from $1.25 Billion to $ 393.66 Million, with a yearly change of -10.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $393.66 Million | +125.94% |
| 2025 | $174.23 Million | -63.88% |
| 2024 | $482.34 Million | -46.18% |
| 2023 | $896.18 Million | +85.91% |
| 2022 | $482.06 Million | -54.17% |
| 2021 | $1.05 Billion | -14.68% |
| 2020 | $1.23 Billion | +299.08% |
| 2019 | $308.96 Million | +139.96% |
| 2018 | $128.76 Million | -43.02% |
| 2017 | $225.96 Million | -45.92% |
| 2016 | $417.82 Million | -66.56% |
| 2015 | $1.25 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 26th, 2026 the market cap of Arcturus Therapeutics Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $393.66 Million USD |
| MoneyControl | $393.66 Million USD |
| MarketWatch | $393.66 Million USD |
| marketcap.company | $393.66 Million USD |
| Reuters | $393.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 cli… Read more